BLUE Quote, Trading Chart, bluebird bio Inc.

$33.17 Last:

0.06% Change Percent:

$33.03 Open:

$33.17 Previous Close:

$33.58 High:

$32.79 Low:

949,961 Volume:

06/21/2021 04:42:41 am Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2021-06-21	33.03	33.17	33.58	32.79	949,961
2021-06-18	32.68	33.15	33.43	32.23	1,217,079
2021-06-17	32.59	32.98	33.4	32.47	530,781
2021-06-16	32.6	32.78	33.23	31.94	869,499
2021-06-15	33.37	32.83	33.6797	32.69	1,857,801
2021-06-14	33.83	33.53	35.5883	33.2	2,260,819
2021-06-11	34.25	34.1	34.37	33.3006	1,248,882
2021-06-10	32.99	33.89	34.5	32.8218	1,292,561
2021-06-09	32.8	32.97	34.29	32.39	2,362,107
2021-06-08	32.41	32.81	32.92	31.4401	1,496,631
2021-06-07	32.4202	31.98	32.57	30.25	3,815,749
2021-06-04	30.99	30.92	31.32	30.46	560,208
2021-06-03	30.87	30.7	31.22	30.11	789,899
2021-06-02	31.09	31.14	31.491	30.735	796,616
2021-06-01	31.05	31.11	31.695	30.91	910,878
2021-05-31	31.81	31.12	32.73	31.08	811,330
2021-05-28	31.81	31.12	32.73	31.08	810,577
2021-05-27	31.01	31.72	31.8	30.56	986,830
2021-05-26	30.65	31.03	31.3055	30.53	550,339
2021-05-25	30.87	30.52	31	30.43	741,105

Stock Information

bluebird bio Inc. Company Name:

BLUE Stock Symbol:

NASDAQ Market:

bluebird bio Inc. Website:

BLUE Quote, Trading Chart, bluebird bio Inc.

Get BLUE Alerts

News, Short Squeeze, Breakout and More Instantly...

BLUE - Is bluebird bio's Surge a Bellwether for Gene Editing Stocks?

Pioneering biotech bluebird bio (NASDAQ: BLUE) has resumed clinical trials for its blood disorder gene therapies after getting clearance from the U.S. Food and Drug Administration (FDA). The stock is up more than 10% over the past five days in response, and the FDA's move bodes well...
BLUE - BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE). In May 2020, the Company announced its plans t...
BLUE - betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for ?-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual

With 51 patients enrolled, data from the long-term follow-up study (LTF-303) show that all patients treated with beti-cel who achieve transfusion independence (TI) remain free from transfusions, with the longest follow-up of seven years Across Phase 3 studies, 89% (32/36) of...